Page last updated: 2024-12-06

ubenimex

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ubenimex is a synthetic derivative of the natural product, L-proline. It was initially developed as an anti-tumor agent, and it was found to have an inhibitory effect on the biosynthesis of dihydrofolate reductase, an enzyme essential for DNA synthesis. While its anti-tumor activity was modest, subsequent research focused on its immunomodulatory properties. Ubenimex has shown to stimulate the immune system by increasing the production of cytokines, such as interleukin-2, and by enhancing the activity of natural killer cells. This has led to its exploration in the treatment of various autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. Ubenimex is currently in clinical trials for several conditions, and its potential therapeutic applications are being investigated.'

ubenimex: growth inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11957481
CHEMBL ID538595
CHEBI ID180575
SCHEMBL ID3880484
MeSH IDM0059108
PubMed CID72172
CHEMBL ID29292
SCHEMBL ID7944
MeSH IDM0059108

Synonyms (157)

Synonym
bestatin (hydrochloride)
CHEBI:180575
(2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid;hydrochloride
EU-0100214
bestatin hydrochloride, >=98% (hplc)
bestatin hydrochloride
NCGC00093685-01
n-[(2s,3r)-3-amino-2-hydroxy-4-phenylbutyryl]-l-leucine hydrochloride
B 8385
CHEMBL538595
B-2270
ubenimex hydrochloride
M01391
65391-42-6
LP00214
CCG-207863
CS-1911
HY-B0134A
SCHEMBL3880484
NCGC00260899-01
tox21_500214
ubenimex hcl
B4000
mfcd00058004
bestatin monohydrochloride
AKOS030526173
sr-01000075724
SR-01000075724-2
bestatin, [(2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl]-l-leucine hydrochloride
(2s)-2-[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanoic acid hydrochloride
AS-57675
H11007
SR-01000075724-1
(s)-2-((2s,3r)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid hydrochloride
65391-42-6 (hcl)
((2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl)-l-leucine hydrochloride
bestatin hcl
SR-01000075724-6
l-leucine, n-((2s,3r)-3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, hydrochloride (1:1)
l-leucine, n-((2s,3r)-3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, monohydrochloride
A914271
BB164242
bestatin hydrochloride- bio-x
HMS3268O06
BRD-K59574735-001-02-7
nsc-265489
ubestatin
smr000059165
MLS000028649
l-leucine, n-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, (s-(r*,s*))-
(s-(r*,s*))-n-(3-amino-2-hydroxy-4-phenylbutyroyl)-l-leucine
3-(r)-amino-2-(s)-hydroxy-4-phenylbutanoyl-(s)-leucine
einecs 261-529-2
(-)-n-((2s,3r)-3-amino-2-hydroxy-4-phenylbutyryl)-l-leucine
nsc 265489
nk 421
(3-amino-2-hydroxy-4-phenylbutanoyl)-l-leucine
ubenimex [inn:jan]
brn 4704312
ubenimexum [latin]
NCGC00025323-01
BIO2_000753
BIO2_000273
IDI1_034023
SMP1_000030
BSPBIO_001553
bdbm23971
(2s)-2-[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanoic acid
chembl29292 ,
BCBCMAP01_000178
LOPAC0_000214
bestatin ,
(2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid
nk-421
2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid
MLS001424177
58970-76-6
ubenimex
n-[(2s,3r)-3-amino-2-hydroxy-4-phenylbutyryl]-l-leucine, 97%
DB03424
1TXR
NCGC00025323-03
KBIO2_002841
KBIO3_000545
KBIOSS_000273
KBIOGR_000273
KBIO2_005409
KBIO3_000546
KBIO2_000273
NCGC00025323-02
NCGC00025323-04
HMS1989N15
HMS2052A03
NCGC00025323-05
(-)-bestatin
(2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
HMS1361N15
HMS1791N15
A832093
n-[(2s,3r)-3-amino-2-hydroxy-1-oxo-4-phenylbutyl]-l-leucine
HMS2232H13
CCG-101071
unii-i0j33n5627
i0j33n5627 ,
ubenimexum
bdbm50367209
n-[(2s,3r)-3-amino-2-hydroxy-4-phenylbutyryl]-l-leucine
ubenimex(bestatin)
BCP0726000308
NCGC00025323-06
S1591
AKOS016339610
HY-B0134
CS-1910
MLS006010137
NC00321
SCHEMBL7944
KS-5207
ubenimex, bestatin
VGGGPCQERPFHOB-RDBSUJKOSA-N
(s)-2-((2s,3r)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid
W-105351
l-leucine, n-[(2s,3r)-3-amino-2-hydroxy-1-oxo-4-phenylbutyl]-
HMS3402N15
ubenimex [inn]
n-((2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl)-leucine
ubenimex [jan]
ubenimex [mart.]
l-leucine, n-((2s,3r)-3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-
ubenimex [mi]
AB00698345_05
ubenimex [who-dd]
EX-A1292
ubenimex, solid
SR-01000075724-3
HMS3715B20
((2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl)-l-leucine
n-[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl]-l-leucine
58970-76-6 (free base)
ubenimex (bestatin) ,
HMS3676N16
ubenimex,(s)
HMS3412N16
Q10909912
BRD-K59574735-001-05-0
SDCCGSBI-0050202.P003
NCGC00025323-14
NCGC00025323-08
[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl]-leu
nsc-779839
nsc779839
EN300-7388593
ubenimex- bio-x
BU164499
(s)-2-((2s,3r)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoicacid
U0111
Z2242062173

Research Excerpts

Overview

Ubenimex is a dipeptide with the ability to inhibit aminopeptidase N (APN) activity, enhance the function of immunocompetent cells and confer antitumor effects.

ExcerptReferenceRelevance
"Ubenimex is a low-molecular-weight dipeptide with the ability to inhibit aminopeptidase N (APN) activity, enhance the function of immunocompetent cells and confer antitumor effects. "( Ubenimex inhibits cell proliferation, migration and invasion in renal cell carcinoma: the effect is autophagy-associated.
Liu, S; Liu, X; Liu, Z; Niu, Z; Sun, L; Wang, H; Xie, F, 2015
)
3.3
"Ubenimex is a dipeptide ((2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine) and an inhibitor of aminopeptidase B produced by Streptomyces olivoreticuli."( Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells.
Iida-Tanaka, K; Irino, S; Kubota, Y; Murata, M; Takahara, J; Tanaka, T, 1994
)
1.41
"Ubenimex is an orally active aminopeptidase inhibitor with an immunomodulating action. "( Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome.
Fukushima, T; Gotoh, N; Iwasaki, H; Kimura, S; Okumura, E; Tohyama, K; Tsutani, H; Ueda, T; Urasaki, Y; Wano, Y,
)
1.81
"Ubenimex (Bestatin) is a potent inhibitor of aminopeptidases (APase) including APase N (EC 3.4.11.2), a widely distributed membrane-bound metalloprotease. "( Ubenimex (Bestatin), an aminopeptidase inhibitor, modulates protein kinase C in K562 cells.
Kumano, N; Sugawara, S,
)
3.02
"Ubenimex is a low molecular biological response modifier (BRM) which has been demonstrated to have antitumor and immunomodulatory activities. "( Enhancement of host resistance to opportunistic infections by ubenimex (bestatin).
Abe, F; Abe, S; Aoyagi, K; Ikeda, T; Ishizuka, M; Ito, N; Takeuchi, T; Uchida, K; Yamaguchi, H, 1992
)
1.97
"Ubenimex is a low molecular weight microbial metabolite which has been demonstrated to have antitumor and immunomodulatory activities. "( Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection.
Abe, F; Abe, S; Aoyagi, K; Ishizuka, M; Itoh, N; Takeuchi, T; Uchida, K; Yamaguchi, H, 1992
)
2.08

Actions

ExcerptReferenceRelevance
"Ubenimex, which can inhibit several aminopeptidases, also reduced the liberated amino acids to about 50 per cent."( Possible involvement of placental peptidases that degrade gonadotropin-releasing hormone (GnRH) in the dynamic pattern of placental hCG secretion via GnRH degradation.
Ino, K; Itakura, A; Ito, M; Kajiyama, H; Kikkawa, F; Mizutani, S; Nomura, S; Tsujimoto, M; Watanabe, Y, 2002
)
1.04

Treatment

Ubenimex-treated mice had a significant increase in number of peritoneal exudate cells with neutrophils as well as enhanced functions, including phagocytosis and active oxygen production. Treatment with ubenimeX was accompanied by decreased Akt expression, indicating that ubenimx may have similar functions to Akt inhibitors.

ExcerptReferenceRelevance
"Ubenimex-treated U937 cells showed condensation of nuclear chromatin, increase of cytoplasmic vacuoles and more intense nonspecific esterase staining compared with untreated U937 cells."( Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells.
Iida-Tanaka, K; Irino, S; Kubota, Y; Murata, M; Takahara, J; Tanaka, T, 1994
)
1.41
"Ubenimex-treated mice had a significant increase in number of peritoneal exudate cells with neutrophils as well as enhanced functions, including phagocytosis and active oxygen production."( Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection.
Abe, F; Abe, S; Aoyagi, K; Ishizuka, M; Itoh, N; Takeuchi, T; Uchida, K; Yamaguchi, H, 1992
)
1.36
"Treatment with ubenimex was accompanied by decreased Akt expression, indicating that ubenimex may have similar functions to Akt inhibitors."( Ubenimex, an APN inhibitor, could serve as an anti‑tumor drug in RT112 and 5637 cells by operating in an Akt‑associated manner.
Cui, M; Guo, F; Liu, S; Liu, W; Liu, Y; Wang, X; Wu, R; Zhang, L; Zhang, Y, 2018
)
2.26

Toxicity

ExcerptReferenceRelevance
" Mice and rats were observed for 14 days after treatment and LD50 values were calculated by the probit method."( Toxicological studies on bestatin. I. Acute toxicity test in mice, rats and dogs.
Hagiwara, T; Hayashi, M; Irie, Y; Ito, K; Kishi, H; Sakai, Y; Sakakibara, T; Sakamoto, M; Suzuki, M, 1983
)
0.27
" Toxicological studies involving examination of skin sensitization, acute skin irritation/corrosion, acute dermal toxicity, acute oral toxicity and acute eye irritation/corrosion established that compound 3b is safe for use."( Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
Guśpiel, A; Jarończyk, M; Jarosz, J; Kawęcki, R; Nasulewicz-Goldeman, A; Pypowski, K; Solecka, J; Wietrzyk, J; Ziemska, J, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" A pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex was performed in patients with myelodysplastic syndrome."( Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome.
Fukushima, T; Gotoh, N; Iwasaki, H; Kimura, S; Okumura, E; Tohyama, K; Tsutani, H; Ueda, T; Urasaki, Y; Wano, Y,
)
0.6
" The method was successfully applied to pharmacokinetic study of bestatin in rats."( Development of a liquid chromatography/tandem mass spectrometry assay for the determination of bestatin in rat plasma and its application to a pharmacokinetic study.
Chen, Y; Fan, G; Lin, M; Wang, C; Wu, Y; Zhao, W, 2007
)
0.34

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effect of bleomycin against Ehrlich ascites carcinoma transplanted subcutaneously to mice used in combination with bestatin was investigated."( The antitumor effect of bleomycin combined with bestatin against Ehrlich ascites carcinoma in mice.
Akin, C; Altuğ, T; Devrim, S; Kaya, G, 1988
)
0.27
"Biological effect of bestatin in combination with bleomycin against rat ascites hepatoma AH 66 was investigated."( [Antitumor effect of bestatin combined with bleomycin against hepatoma AH 66 subcutaneously transplanted in rats].
Abe, F; Ichikawa, T; Matsuda, A; Takahashi, K; Umezawa, H; Yamashita, T, 1984
)
0.27
"To prevent postoperative recurrence a randomized prospective trial was performed on 45 patients with bladder cancers by dividing them into 2 groups given either UFT therapy alone or UFT therapy in combination with Bestatin."( Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin.
Koshida, K; Kunimi, K; Uchibayashi, T; Yamamoto, H, 1995
)
0.29
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"The purpose of the present study was to elucidate the transporter-mediated pharmacokinetics mechanism of drug-drug interactions (DDIs) between bestatin and cefixime."( PEPT1- and OAT1/3-mediated drug-drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human.
Huo, X; Liu, K; Liu, Q; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C; Wang, L; Yang, X; Zhen, Y, 2014
)
0.4
" In mouse hepatoma H22 model, the triple drug combination showed synergistic and highly potent antitumor efficacy."( A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice.
Li, Y; Liu, XJ; Wu, SY; Zhen, YS; Zheng, YB, 2014
)
0.4
" A drug combination offers a new strategy for appropriate use of 5-FU."( Enhanced anticancer activity of 5-FU in combination with Bestatin: Evidence in human tumor-derived cell lines and an H22 tumor-bearing mouse.
Hou, J; Huang, Y; Li, J; Wang, X; Xu, W; Zhang, Y, 2015
)
0.42
" The results of this study demonstrated that UBE combined with fluorouracil attenuated multiple drug resistance and inhibited the expression of P-gp in lung cancer."( Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P-glycoprotein expression level in non-small lung cancer.
Ding, GG; Ling, XA; Wan, J; Wang, J; Wang, X, 2020
)
0.88
" Standardised treatments combined with ubenimex may improve the survival rate of patients with malignant tumors."( Efficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors.
Hu, X; Huang, S; Mao, T; Su, T; Xiong, H; Yang, L, 2021
)
1.14

Bioavailability

ExcerptReferenceRelevance
"Aminopeptidase inhibitors may be useful for improving the systemic bioavailability of peptide drugs administered nasally or by other routes."( Recovery of rat nasal mucosa from the effects of aminopeptidase inhibitors.
Aungst, BJ; Hussain, MA; Koval, CA; Shenvi, AB, 1990
)
0.28
" The increase in peak height was calculated relative to nasal administration of hGH alone without any enhancers and the relative bioavailability was calculated with reference to subcutaneous injection data."( Nasal absorption enhancers for biosynthetic human growth hormone in rats.
Critchley, H; Davis, SS; Farraj, NF; Fisher, AN; Illum, L; Johansen, BR; O'Hagan, DT, 1990
)
0.28
" CHR-2797 is orally bioavailable and currently undergoing phase II clinical investigation in the treatment of myeloid leukemia."( CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
Ayscough, A; Bawden, LJ; Bone, EA; Box, G; Callaghan, J; Chandler, S; Clark, VL; Drummond, AH; Eccles, SA; Farmer, H; Flores, N; Kirwin-Jones, P; Krige, D; Laber, D; Legris, V; Miles, LE; Needham, LA; Odedra, R; Owen, J; Patel, T; Stone, E; Wood, LM; Wood, S; Wright, A, 2008
)
0.35
"Peptidomimetic drugs have favorable bioavailability owing to H(+)/peptide transporter 1 (PEPT1) located in the intestine."( Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats.
Huo, X; Liu, K; Liu, Q; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C, 2014
)
0.4
" Bioavailability of leuprolide following pulmonary administration was 75% higher compared to subcutaneously administered leuprolide."( Effect of protease inhibitors on pulmonary bioavailability of therapeutic proteins and peptides in the rat.
Amancha, KP; Hussain, A, 2015
)
0.42
" The relative bioavailability F(0-t) and F(0-∞) of T1 and T2 against the branded preparation R were (103."( [Bioequivalence of Ubenimex Capsules in Healthy Volunteers].
Hu, C; Miao, J; Nan, F; Qin, YP; Shu, SQ; Wang, Y; Xiang, J; Yu, Q; Zheng, J; Zhu, XH, 2016
)
0.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" dosage form."( H+ coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes.
Hori, R; Inui, K; Katsura, T; Okano, T; Takano, M; Tomita, Y, 1992
)
0.28
" We conclude that Bestatin at this dosage does not improve the immunological functions or clinical outcome in patients with hydatidiform mole."( A controlled trial of bestatin in hydatidiform mole.
Ho, PC; Lawton, JW; Ma, HK; Wong, LC, 1990
)
0.28
" Dose-response experiments revealed two active ranges from 1 ng/kg to 100 ng/kg and from 10 micrograms/kg to 10 mg/kg or more."( Enhancement of antibody formation against herpes simplex virus in mice by the T-cell mitogen bestatin.
Falke, D; Harle-Grupp, V; Knoblich, A; Müller, WE, 1984
)
0.27
" As general symptoms, loss of appetite, vomiting, abnormal feces (loose stool, diarrhea, mucous stool), eye mucus, decoloration of the visible mucous membrance and unkempt fur were observed slightly and almost dose-dependently in the group dosed with more than 96 mg/kg."( Toxicological studies on bestatin. II. Subacute toxicity test and recovery study in beagle dogs.
Hagiwara, T; Hayashi, M; Irie, Y; Ito, K; Kishi, H; Okada, M; Sakai, Y; Sakakibara, T; Sakamoto, M; Suzuki, M, 1983
)
0.27
" Analysis of changes in immunological parameters at all the tested dosages of Bestatin led to the presumption that its optimal dose was in the low dosage ranging from 10 to 100 mg daily."( [Phase I study of Bestatin: (I) A clinical study on determination of an optimal dose of Bestatin].
Ikeda, S; Miyasato, H; Saito, K; Tajima, K, 1983
)
0.27
" The changes were observed irrespective of the dosage and the number of subsequent doses applied."( Effects of bestatin on phagocytic cells in cyclophosphamide-treated mice.
Lis, M; Obmińska-Mrukowicz, B, 2011
)
0.37
" By dose-response studies, three compounds were identified as potent and selective ePepN inhibitors, as little inhibitory effect was exhibited for the porcine ortholog aminopeptidase."( Discovery of potent and selective inhibitors of the Escherichia coli M1-aminopeptidase via multicomponent solid-phase synthesis of tetrazole-peptidomimetics.
Alonso Del Rivero, M; Álvarez-Ginarte, YM; De Armas, G; de León, L; González-Bacerio, J; Izquierdo, M; Méndez, Y; Pérez, I; Rivera, DG; Rojas, T; Scott, WL; Soto, C; Valdés-Tresanco, ME; Valiente, PA; Vasco, AV; Westermann, B, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (51)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID1705
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.20980.001530.607315,848.9004AID1224819; AID1224820; AID1224821
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency15.101423.934123.934123.9341AID1967
lamin isoform A-delta10Homo sapiens (human)Potency3.81460.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency25.11890.015812.3113615.5000AID1461
Fumarate hydrataseHomo sapiens (human)Potency33.17340.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency23.05110.000811.382244.6684AID686978
EWS/FLI fusion proteinHomo sapiens (human)Potency26.62350.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency33.17340.00308.794948.0869AID1347053
arylsulfatase AHomo sapiens (human)Potency0.84921.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
beta-2 adrenergic receptorHomo sapiens (human)Potency12.99530.00586.026332.6427AID485366
flap endonuclease 1Homo sapiens (human)Potency8.43680.133725.412989.1251AID588795
tyrosine-protein kinase YesHomo sapiens (human)Potency54.67770.00005.018279.2586AID686947
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency16.48160.15855.287912.5893AID493164
plasminogen precursorMus musculus (house mouse)Potency16.48160.15855.287912.5893AID493164
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency16.48160.15855.287912.5893AID493164
gemininHomo sapiens (human)Potency16.48160.004611.374133.4983AID493164
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aminopeptidase NSus scrofa (pig)IC50 (µMol)3.03000.00053.53548.9000AID38227
Aminopeptidase NSus scrofa (pig)Ki5.06670.00052.29697.8000AID38231; AID38232; AID38234
Cytosol aminopeptidaseHomo sapiens (human)Ki20.00000.00060.16010.4200AID101208
Angiotensin-converting enzymeRattus norvegicus (Norway rat)IC50 (µMol)3.03000.00090.33223.0300AID38227
Leukotriene B4 receptor 1Homo sapiens (human)Ki20.00000.00010.51267.0000AID101208
Chain A, Bacterial leucyl aminopeptidaseVibrio proteolyticusKi0.01800.01800.01800.0180AID977610
Aminopeptidase BRattus norvegicus (Norway rat)IC50 (µMol)6.00006.00006.00006.0000AID38213
Aminopeptidase BRattus norvegicus (Norway rat)Ki0.06000.06000.06000.0600AID38222
Histone deacetylase 3Homo sapiens (human)IC50 (µMol)550.00000.00040.619610.0000AID729522; AID764647
M1 family aminopeptidasePlasmodium falciparum FcB1/ColumbiaIC50 (µMol)0.28400.28400.28400.2840AID220436
M1 family aminopeptidasePlasmodium falciparum FcB1/ColumbiaKi0.19000.19000.19000.1900AID587097
Cytosol aminopeptidaseBos taurus (cattle)IC50 (µMol)1.00050.00051.00053.5000AID1798383
Cytosol aminopeptidaseBos taurus (cattle)Ki0.50000.50000.50000.5000AID704972
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)126.52470.00001.284810.0000AID1141241; AID1803043; AID307412; AID339516; AID389010; AID408408; AID415444; AID415653; AID437270; AID453299; AID456587; AID497183; AID613978; AID619826; AID665653; AID712068; AID752014
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)Ki0.01030.00010.03040.1570AID101204; AID101207
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)3.76160.00051.28547.6500AID1322069; AID1337016; AID1337017; AID1658567; AID1798383; AID362195; AID568370; AID724223
Leukotriene A-4 hydrolaseHomo sapiens (human)Ki0.32000.00301.34103.7000AID1322070
Phospholipase A2, membrane associatedHomo sapiens (human)IC50 (µMol)100.00000.00301.08118.0000AID724222
Aminopeptidase NHomo sapiens (human)IC50 (µMol)42.17380.40002.11003.9000AID1276241; AID1348403; AID1348404; AID1497803; AID1497804; AID1500912; AID1572692; AID1572693; AID1713141; AID1713599; AID1713600; AID241143; AID38364; AID38378; AID477788; AID568368; AID613980; AID619827; AID665652; AID712070; AID729521; AID744379; AID752017; AID764645
Aminopeptidase NHomo sapiens (human)Ki2.37000.00081.956910.0000AID1607842
Aminopeptidase NSus scrofa (pig)IC50 (µMol)16.78810.00053.53548.9000AID1141242; AID1248350; AID1348402; AID1713140; AID1713601; AID1774963; AID1798383; AID1802060; AID1803042; AID1803262; AID1803290; AID284233; AID307411; AID339515; AID35686; AID38364; AID389009; AID397940; AID406526; AID414664; AID415443; AID415652; AID440776; AID453298; AID472434; AID497182; AID551696; AID613977; AID619825; AID665651; AID701438; AID712059; AID729523; AID744380; AID752016; AID764648
Aminopeptidase NSus scrofa (pig)Ki3.42610.00052.29697.8000AID1461818; AID38226; AID701437; AID704974; AID779531
Interleukin-1 receptor antagonist proteinHomo sapiens (human)IC50 (µMol)100.00000.25120.25120.2512AID1893373
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)120.40000.00031.38338.4000AID613978
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)324.30000.00010.444410.0000AID56226
Cytosol aminopeptidaseHomo sapiens (human)IC50 (µMol)11.20000.30000.30000.3000AID241862
Cytosol aminopeptidaseHomo sapiens (human)Ki0.01030.00060.16010.4200AID101204; AID101207
Angiotensin-converting enzymeRattus norvegicus (Norway rat)IC50 (µMol)2.70000.00090.33223.0300AID38378
Puromycin-sensitive aminopeptidaseHomo sapiens (human)IC50 (µMol)3.50000.26003.97759.7000AID1500910
Aminopeptidase NMus musculus (house mouse)Ki3.03003.03003.03003.0300AID712132
Leucyl-cystinyl aminopeptidaseRattus norvegicus (Norway rat)Ki2.21000.02001.16504.4000AID101332; AID38354
Bacterial leucyl aminopeptidaseVibrio proteolyticusIC50 (µMol)1.00050.00051.00053.5000AID1798383
Bacterial leucyl aminopeptidaseVibrio proteolyticusKi0.00160.00160.17580.3500AID779530
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)400.00000.00010.55439.9000AID1276240; AID729522; AID764647
Leukotriene B4 receptor 1Homo sapiens (human)Ki0.00710.00010.51267.0000AID101204; AID101207
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki18.00003.00006.47788.5000AID681124
Endoplasmic reticulum aminopeptidase 2Homo sapiens (human)IC50 (µMol)100.00007.94337.94337.9433AID1893372
Histone deacetylase 2Homo sapiens (human)IC50 (µMol)100.00000.00010.72219.9700AID1276240
Histone deacetylase 8Homo sapiens (human)IC50 (µMol)550.00000.00070.99479.9000AID729522; AID764647
Histone deacetylase 5Homo sapiens (human)IC50 (µMol)550.00000.00070.961010.0000AID729522; AID764647
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene A-4 hydrolaseHomo sapiens (human)Kd3.94330.06003.73568.4700AID1322073; AID1322074; AID1322075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (236)

Processvia Protein(s)Taxonomy
proteolysisCytosol aminopeptidaseHomo sapiens (human)
muscle contractionLeukotriene B4 receptor 1Homo sapiens (human)
inflammatory responseLeukotriene B4 receptor 1Homo sapiens (human)
immune responseLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
establishment of mitotic spindle orientationHistone deacetylase 3Homo sapiens (human)
in utero embryonic developmentHistone deacetylase 3Homo sapiens (human)
positive regulation of protein phosphorylationHistone deacetylase 3Homo sapiens (human)
chromatin organizationHistone deacetylase 3Homo sapiens (human)
transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
protein deacetylationHistone deacetylase 3Homo sapiens (human)
regulation of mitotic cell cycleHistone deacetylase 3Homo sapiens (human)
positive regulation of protein ubiquitinationHistone deacetylase 3Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 3Homo sapiens (human)
positive regulation of TOR signalingHistone deacetylase 3Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
regulation of multicellular organism growthHistone deacetylase 3Homo sapiens (human)
positive regulation of protein import into nucleusHistone deacetylase 3Homo sapiens (human)
regulation of circadian rhythmHistone deacetylase 3Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
negative regulation of JNK cascadeHistone deacetylase 3Homo sapiens (human)
spindle assemblyHistone deacetylase 3Homo sapiens (human)
establishment of skin barrierHistone deacetylase 3Homo sapiens (human)
cellular response to fluid shear stressHistone deacetylase 3Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone deacetylase 3Homo sapiens (human)
DNA repair-dependent chromatin remodelingHistone deacetylase 3Homo sapiens (human)
cornified envelope assemblyHistone deacetylase 3Homo sapiens (human)
negative regulation of cardiac muscle cell differentiationHistone deacetylase 3Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
phospholipid metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
inflammatory responsePhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPhospholipase A2, membrane associatedHomo sapiens (human)
lipid catabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
killing of cells of another organismPhospholipase A2, membrane associatedHomo sapiens (human)
low-density lipoprotein particle remodelingPhospholipase A2, membrane associatedHomo sapiens (human)
intestinal stem cell homeostasisPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidylethanolamine metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidylcholine metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidic acid metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
arachidonic acid secretionPhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of inflammatory responsePhospholipase A2, membrane associatedHomo sapiens (human)
defense response to Gram-positive bacteriumPhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePhospholipase A2, membrane associatedHomo sapiens (human)
regulation of neutrophil activationPhospholipase A2, membrane associatedHomo sapiens (human)
negative regulation of T cell proliferationPhospholipase A2, membrane associatedHomo sapiens (human)
angiogenesisAminopeptidase NHomo sapiens (human)
cell differentiationAminopeptidase NHomo sapiens (human)
symbiont entry into host cellAminopeptidase NHomo sapiens (human)
proteolysisAminopeptidase NHomo sapiens (human)
peptide catabolic processAminopeptidase NHomo sapiens (human)
lipid metabolic processInterleukin-1 receptor antagonist proteinHomo sapiens (human)
immune responseInterleukin-1 receptor antagonist proteinHomo sapiens (human)
signal transductionInterleukin-1 receptor antagonist proteinHomo sapiens (human)
insulin secretionInterleukin-1 receptor antagonist proteinHomo sapiens (human)
negative regulation of heterotypic cell-cell adhesionInterleukin-1 receptor antagonist proteinHomo sapiens (human)
response to glucocorticoidInterleukin-1 receptor antagonist proteinHomo sapiens (human)
negative regulation of interleukin-1-mediated signaling pathwayInterleukin-1 receptor antagonist proteinHomo sapiens (human)
inflammatory response to antigenic stimulusInterleukin-1 receptor antagonist proteinHomo sapiens (human)
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
proteolysisCytosol aminopeptidaseHomo sapiens (human)
protein polyubiquitinationPuromycin-sensitive aminopeptidaseHomo sapiens (human)
cellular response to hypoxiaPuromycin-sensitive aminopeptidaseHomo sapiens (human)
positive regulation of protein targeting to mitochondrionPuromycin-sensitive aminopeptidaseHomo sapiens (human)
peptide catabolic processPuromycin-sensitive aminopeptidaseHomo sapiens (human)
proteolysisPuromycin-sensitive aminopeptidaseHomo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
muscle contractionLeukotriene B4 receptor 1Homo sapiens (human)
inflammatory responseLeukotriene B4 receptor 1Homo sapiens (human)
immune responseLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
adaptive immune responseEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
regulation of blood pressureEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
peptide catabolic processEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
proteolysisEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
response to amphetamineHistone deacetylase 2Homo sapiens (human)
cardiac muscle hypertrophyHistone deacetylase 2Homo sapiens (human)
chromatin remodelingHistone deacetylase 2Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 2Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 2Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 2Homo sapiens (human)
negative regulation of neuron projection developmentHistone deacetylase 2Homo sapiens (human)
dendrite developmentHistone deacetylase 2Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 2Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 2Homo sapiens (human)
response to caffeineHistone deacetylase 2Homo sapiens (human)
heterochromatin formationHistone deacetylase 2Homo sapiens (human)
response to lipopolysaccharideHistone deacetylase 2Homo sapiens (human)
positive regulation of interleukin-1 productionHistone deacetylase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionHistone deacetylase 2Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 2Homo sapiens (human)
positive regulation of collagen biosynthetic processHistone deacetylase 2Homo sapiens (human)
cellular response to heatHistone deacetylase 2Homo sapiens (human)
response to nicotineHistone deacetylase 2Homo sapiens (human)
protein modification processHistone deacetylase 2Homo sapiens (human)
response to cocaineHistone deacetylase 2Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinHistone deacetylase 2Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 2Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 2Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of MHC class II biosynthetic processHistone deacetylase 2Homo sapiens (human)
positive regulation of proteolysisHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
behavioral response to ethanolHistone deacetylase 2Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 2Homo sapiens (human)
response to hyperoxiaHistone deacetylase 2Homo sapiens (human)
hair follicle placode formationHistone deacetylase 2Homo sapiens (human)
negative regulation of dendritic spine developmentHistone deacetylase 2Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 2Homo sapiens (human)
fungiform papilla formationHistone deacetylase 2Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 2Homo sapiens (human)
cellular response to retinoic acidHistone deacetylase 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusHistone deacetylase 2Homo sapiens (human)
positive regulation of male mating behaviorHistone deacetylase 2Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
cellular response to dopamineHistone deacetylase 2Homo sapiens (human)
response to amyloid-betaHistone deacetylase 2Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 2Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 8Homo sapiens (human)
chromatin organizationHistone deacetylase 8Homo sapiens (human)
mitotic sister chromatid cohesionHistone deacetylase 8Homo sapiens (human)
negative regulation of protein ubiquitinationHistone deacetylase 8Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 8Homo sapiens (human)
regulation of telomere maintenanceHistone deacetylase 8Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 8Homo sapiens (human)
proteolysisAminopeptidase BHomo sapiens (human)
angiogenesisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
adaptive immune responseEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
membrane protein ectodomain proteolysisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
regulation of blood pressureEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
response to bacteriumEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
regulation of innate immune responseEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
fat cell differentiationEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
positive regulation of angiogenesisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
peptide catabolic processEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
proteolysisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
inflammatory responseHistone deacetylase 5Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 5Homo sapiens (human)
regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
response to activityHistone deacetylase 5Homo sapiens (human)
neuron differentiationHistone deacetylase 5Homo sapiens (human)
B cell differentiationHistone deacetylase 5Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 5Homo sapiens (human)
B cell activationHistone deacetylase 5Homo sapiens (human)
response to cocaineHistone deacetylase 5Homo sapiens (human)
regulation of protein bindingHistone deacetylase 5Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 5Homo sapiens (human)
cellular response to lipopolysaccharideHistone deacetylase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (79)

Processvia Protein(s)Taxonomy
aminopeptidase activityCytosol aminopeptidaseHomo sapiens (human)
carboxypeptidase activityCytosol aminopeptidaseHomo sapiens (human)
protein bindingCytosol aminopeptidaseHomo sapiens (human)
metalloexopeptidase activityCytosol aminopeptidaseHomo sapiens (human)
manganese ion bindingCytosol aminopeptidaseHomo sapiens (human)
metalloaminopeptidase activityCytosol aminopeptidaseHomo sapiens (human)
peptidase activityCytosol aminopeptidaseHomo sapiens (human)
nucleotide bindingLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 3Homo sapiens (human)
chromatin bindingHistone deacetylase 3Homo sapiens (human)
transcription corepressor activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase activityHistone deacetylase 3Homo sapiens (human)
protein bindingHistone deacetylase 3Homo sapiens (human)
enzyme bindingHistone deacetylase 3Homo sapiens (human)
cyclin bindingHistone deacetylase 3Homo sapiens (human)
chromatin DNA bindingHistone deacetylase 3Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 3Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 3Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 3Homo sapiens (human)
protein decrotonylase activityHistone deacetylase 3Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 3Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 3Homo sapiens (human)
carboxypeptidase activityCytosol aminopeptidaseBos taurus (cattle)
peptidase activityCytosol aminopeptidaseBos taurus (cattle)
dipeptidase activityCytosol aminopeptidaseBos taurus (cattle)
manganese ion bindingCytosol aminopeptidaseBos taurus (cattle)
metalloaminopeptidase activityCytosol aminopeptidaseBos taurus (cattle)
disordered domain specific bindingCytosol aminopeptidaseBos taurus (cattle)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
phospholipase A2 activityPhospholipase A2, membrane associatedHomo sapiens (human)
phospholipid bindingPhospholipase A2, membrane associatedHomo sapiens (human)
calcium-dependent phospholipase A2 activityPhospholipase A2, membrane associatedHomo sapiens (human)
calcium ion bindingPhospholipase A2, membrane associatedHomo sapiens (human)
virus receptor activityAminopeptidase NHomo sapiens (human)
aminopeptidase activityAminopeptidase NHomo sapiens (human)
metallopeptidase activityAminopeptidase NHomo sapiens (human)
signaling receptor activityAminopeptidase NHomo sapiens (human)
metalloaminopeptidase activityAminopeptidase NHomo sapiens (human)
zinc ion bindingAminopeptidase NHomo sapiens (human)
peptide bindingAminopeptidase NHomo sapiens (human)
cytokine activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1, type I receptor bindingInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1, type II receptor bindingInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1 receptor antagonist activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
protein bindingInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1 type I receptor antagonist activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1 type II receptor antagonist activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityCytosol aminopeptidaseHomo sapiens (human)
carboxypeptidase activityCytosol aminopeptidaseHomo sapiens (human)
protein bindingCytosol aminopeptidaseHomo sapiens (human)
metalloexopeptidase activityCytosol aminopeptidaseHomo sapiens (human)
manganese ion bindingCytosol aminopeptidaseHomo sapiens (human)
metalloaminopeptidase activityCytosol aminopeptidaseHomo sapiens (human)
peptidase activityCytosol aminopeptidaseHomo sapiens (human)
aminopeptidase activityPuromycin-sensitive aminopeptidaseHomo sapiens (human)
zinc ion bindingPuromycin-sensitive aminopeptidaseHomo sapiens (human)
metalloaminopeptidase activityPuromycin-sensitive aminopeptidaseHomo sapiens (human)
peptide bindingPuromycin-sensitive aminopeptidaseHomo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
nucleotide bindingLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
endopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
aminopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
protein bindingEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
metallopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
zinc ion bindingEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
metalloaminopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
peptide bindingEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 2Homo sapiens (human)
chromatin bindingHistone deacetylase 2Homo sapiens (human)
RNA bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 2Homo sapiens (human)
protein bindingHistone deacetylase 2Homo sapiens (human)
enzyme bindingHistone deacetylase 2Homo sapiens (human)
heat shock protein bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 2Homo sapiens (human)
histone bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 2Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 2Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 2Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 2Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 8Homo sapiens (human)
protein bindingHistone deacetylase 8Homo sapiens (human)
Hsp70 protein bindingHistone deacetylase 8Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 8Homo sapiens (human)
metal ion bindingHistone deacetylase 8Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 8Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 8Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 8Homo sapiens (human)
aminopeptidase activityAminopeptidase BHomo sapiens (human)
epoxide hydrolase activityAminopeptidase BHomo sapiens (human)
metalloexopeptidase activityAminopeptidase BHomo sapiens (human)
zinc ion bindingAminopeptidase BHomo sapiens (human)
metalloaminopeptidase activityAminopeptidase BHomo sapiens (human)
endopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
aminopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
interleukin-6 receptor bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
interleukin-1, type II receptor bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
protein bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
metalloexopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
zinc ion bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
peptide bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
metalloaminopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 5Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 5Homo sapiens (human)
chromatin bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase activityHistone deacetylase 5Homo sapiens (human)
protein kinase C bindingHistone deacetylase 5Homo sapiens (human)
protein bindingHistone deacetylase 5Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 5Homo sapiens (human)
identical protein bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 5Homo sapiens (human)
metal ion bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (53)

Processvia Protein(s)Taxonomy
nucleusCytosol aminopeptidaseHomo sapiens (human)
trans-Golgi networkCytosol aminopeptidaseHomo sapiens (human)
focal adhesionCytosol aminopeptidaseHomo sapiens (human)
extracellular exosomeCytosol aminopeptidaseHomo sapiens (human)
cytoplasmCytosol aminopeptidaseHomo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
nucleusHistone deacetylase 3Homo sapiens (human)
nucleoplasmHistone deacetylase 3Homo sapiens (human)
cytoplasmHistone deacetylase 3Homo sapiens (human)
Golgi apparatusHistone deacetylase 3Homo sapiens (human)
cytosolHistone deacetylase 3Homo sapiens (human)
plasma membraneHistone deacetylase 3Homo sapiens (human)
mitotic spindleHistone deacetylase 3Homo sapiens (human)
histone deacetylase complexHistone deacetylase 3Homo sapiens (human)
transcription repressor complexHistone deacetylase 3Homo sapiens (human)
nucleusHistone deacetylase 3Homo sapiens (human)
cytoplasmCytosol aminopeptidaseBos taurus (cattle)
mitochondrionCytosol aminopeptidaseBos taurus (cattle)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular regionPhospholipase A2, membrane associatedHomo sapiens (human)
extracellular spacePhospholipase A2, membrane associatedHomo sapiens (human)
mitochondrial outer membranePhospholipase A2, membrane associatedHomo sapiens (human)
endoplasmic reticulumPhospholipase A2, membrane associatedHomo sapiens (human)
endoplasmic reticulum membranePhospholipase A2, membrane associatedHomo sapiens (human)
plasma membranePhospholipase A2, membrane associatedHomo sapiens (human)
secretory granulePhospholipase A2, membrane associatedHomo sapiens (human)
perinuclear region of cytoplasmPhospholipase A2, membrane associatedHomo sapiens (human)
extracellular exosomePhospholipase A2, membrane associatedHomo sapiens (human)
extracellular spaceAminopeptidase NHomo sapiens (human)
lysosomal membraneAminopeptidase NHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentAminopeptidase NHomo sapiens (human)
plasma membraneAminopeptidase NHomo sapiens (human)
external side of plasma membraneAminopeptidase NHomo sapiens (human)
secretory granule membraneAminopeptidase NHomo sapiens (human)
extracellular exosomeAminopeptidase NHomo sapiens (human)
cytoplasmAminopeptidase NHomo sapiens (human)
plasma membraneAminopeptidase NHomo sapiens (human)
extracellular spaceAminopeptidase NHomo sapiens (human)
extracellular spaceInterleukin-1 receptor antagonist proteinHomo sapiens (human)
nucleoplasmInterleukin-1 receptor antagonist proteinHomo sapiens (human)
centrosomeInterleukin-1 receptor antagonist proteinHomo sapiens (human)
cytosolInterleukin-1 receptor antagonist proteinHomo sapiens (human)
plasma membraneInterleukin-1 receptor antagonist proteinHomo sapiens (human)
extracellular exosomeInterleukin-1 receptor antagonist proteinHomo sapiens (human)
extracellular spaceInterleukin-1 receptor antagonist proteinHomo sapiens (human)
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
nucleusCytosol aminopeptidaseHomo sapiens (human)
trans-Golgi networkCytosol aminopeptidaseHomo sapiens (human)
focal adhesionCytosol aminopeptidaseHomo sapiens (human)
extracellular exosomeCytosol aminopeptidaseHomo sapiens (human)
cytoplasmCytosol aminopeptidaseHomo sapiens (human)
nucleusPuromycin-sensitive aminopeptidaseHomo sapiens (human)
cytosolPuromycin-sensitive aminopeptidaseHomo sapiens (human)
extracellular exosomePuromycin-sensitive aminopeptidaseHomo sapiens (human)
extracellular spacePuromycin-sensitive aminopeptidaseHomo sapiens (human)
cytoplasmPuromycin-sensitive aminopeptidaseHomo sapiens (human)
membranePuromycin-sensitive aminopeptidaseHomo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
endoplasmic reticulum lumenEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
endoplasmic reticulum membraneEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
extracellular spaceEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
membraneEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
cytoplasmEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
chromosome, telomeric regionHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleoplasmHistone deacetylase 2Homo sapiens (human)
cytoplasmHistone deacetylase 2Homo sapiens (human)
NuRD complexHistone deacetylase 2Homo sapiens (human)
Sin3-type complexHistone deacetylase 2Homo sapiens (human)
histone deacetylase complexHistone deacetylase 2Homo sapiens (human)
chromatinHistone deacetylase 2Homo sapiens (human)
protein-containing complexHistone deacetylase 2Homo sapiens (human)
ESC/E(Z) complexHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nuclear chromosomeHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleoplasmHistone deacetylase 8Homo sapiens (human)
cytoplasmHistone deacetylase 8Homo sapiens (human)
histone deacetylase complexHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
extracellular regionAminopeptidase BHomo sapiens (human)
plasma membraneAminopeptidase BHomo sapiens (human)
extracellular exosomeAminopeptidase BHomo sapiens (human)
extracellular spaceAminopeptidase BHomo sapiens (human)
extracellular regionEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
extracellular spaceEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
endoplasmic reticulumEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
endoplasmic reticulum lumenEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
endoplasmic reticulum membraneEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
cytosolEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
membraneEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
extracellular exosomeEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
extracellular spaceEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
cytoplasmEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
membraneEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
nucleusHistone deacetylase 5Homo sapiens (human)
nucleoplasmHistone deacetylase 5Homo sapiens (human)
cytoplasmHistone deacetylase 5Homo sapiens (human)
Golgi apparatusHistone deacetylase 5Homo sapiens (human)
cytosolHistone deacetylase 5Homo sapiens (human)
nuclear speckHistone deacetylase 5Homo sapiens (human)
histone deacetylase complexHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (503)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID101208Compound was evaluated for the inhibition of Leucine aminopeptidase and the inhibition constant was determined after preincubating the enzyme and inhibitor1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes.
AID38232Effect of inhibitor structure on the slow binding inhibition of aminopeptidase M was determined and the Ki was reported which is = k2/k11984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes.
AID38234Compound was evaluated for the inhibition of Aminopeptidase M (AP-M) and the inhibition constant was determined after preincubating the enzyme and inhibitor Value in the parentheses is IC50 (uM).1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID303425Antimalarial activity against Plasmodium chabaudi chabaudi in C57BL/6J mice (Mus musculus) assessed as parasitemia on day 8 at 2 mg, intraperitoneally twice daily for 7 days2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID303421Antimalarial activity after 48 hrs against Plasmodium falciparum D10 by [3H]hypoxanthine uptake2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
AID303420Antimalarial activity after 48 hrs against multidrug-resistant Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
AID38227Compound was evaluated for the inhibitory activity against aminopeptidase M1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes.
AID303423Inhibition of Plasmodium falciparum recombinant M17 LAP2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
AID303429Toxicity in Plasmodium chabaudi chabaudi infected C57BL/6J mice (Mus musculus) at 2 mg, intraperitoneally twice daily after 7 days2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID38231Effect of inhibitor structure on the slow binding inhibition of aminopeptidase M was determined and Ki* was reported which is obtained by the equation Ki[k4/(k3 + k4)]1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID303430Toxicity in Plasmodium chabaudi chabaudi infected C57BL/6J mice (Mus musculus) at 0.1 mg, intraperitoneally twice daily after 4 days2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID303422Antimalarial activity after 48 hrs against drug-sensitive Plasmodium falciparum 3D7 by [3H]hypoxanthine uptake2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1713595Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID397940Inhibition of pig kidney microsomal Aminopeptidase N2009Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11
Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors.
AID619828Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.
AID712131Inhibition of APN in porcine kidney microsome assessed as inhibition of L-Leu-p-nitroanilide substrate hydrolysis incubated for 5 mins before substrate addition by UV-Vis spectrophotometric analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1348421Antiproliferative activity against human H7402 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1303022Inhibition of aminopeptidase B (unknown origin)2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Stacking with No Planarity?
AID1141242Inhibition of pig kidney microsomal APN using L-Leu-p-nitroanilide as substrate preincubated for 5 mins before substrate addition measured after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
AID1461815Inhibition of recombinant Plasmodium falciparum M1 aminopeptidase using Ala-AMC as substrate pretreated for 30 mins followed by substrate addition by fluorescence assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID1713149Antiproliferative activity against human HCT-116 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID573049Inhibition of alanyl aminopeptidase activity in Plasmodium falciparum 3D7 at 10 uM using Ala-AMC as a substrate by spectrophotometer2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
AID752014Inhibition of recombinant MMP2 (unknown origin) using L-Leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 60 mins by UV-Vis spectrophotometry2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID230954Ratio was measured as IC50PfA-M1/IC50APN2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors.
AID712061Inhibition of mouse 3LL cell invasion at 100 mg/ml by Matrigel invasion assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID701227Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 300 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 33.25%)2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID1348445Downregulation of CD13 expression in human PLC/PRF/5 cells at 10 uM in presence of 5-FU after 48 hrs by flow cytometric method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID241862Inhibitory concentration against adipocyte-derived leucine aminopeptidase2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID220436Inhibitory activity for Plasmodium falciparum Zinc aminopeptidase2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors.
AID712057Cytotoxicity against mouse B16-BL6 cells assessed as cell growth inhibition after 24 hrs by MTT assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1322074Binding affinity to human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H at 25 degC by ITC method2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID701228Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1 phase at 300 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 48.40%)2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID386439Antimalarial activity as DNA content of ring stage Plasmodium falciparum 3D7 in medium + isoleucine by flow cytometry2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID729521Inhibition of aminopeptidase N in human ES2 cells using L-leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1713156Anti-angiogenesis activity in HUVEC assessed as inhibition of capillary like tube formation at 30 uM incubated for 6 hrs by matrigel based capillary tube formation assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID752009Antiangiogenic activity against Sprague-Dawley rat aortic rings assessed as inhibition of new microvessel growth at 100 ug/ml after 6 days2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID1713153Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1248353Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1845879Inhibition of recombinant Plasmodium falciparum A-M17 assessed as inhibition constant using H-Leu-NHMec as substrate2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Metalloaminopeptidases of the Protozoan Parasite
AID214560In vitro cytotoxicity towards U937 cell growth was evaluated after 3 days of incubation (10e-4 M)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13.
AID453300Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.
AID1248355Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate at 10 uM incubated for 2 hrs prior to substrate addition measured after 30 mins by fluorescence assay relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1322069Inhibition of human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H using L-arginine-7-amino-4-Methylcoumarine as substrate preincubated for 30 mins followed by substrate addition measured for 30 mins by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID744376Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN).
AID738654Antiangiogenic activity against human HUVEC cells assessed as inhibition of capillary tube formation at 300 uM after 24 hrs by phase contrast microscopic analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy.
AID472436Cytotoxicity against human HT1080 cells assessed as cell growth inhibition after 72 hrs by XTT assay2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13.
AID711161Antimalarial activity against Plasmodium falciparum 3D7 infected in human O positive erythrocytes under low oxygen atmosphere after 72 hrs by spectrophotometric analysis2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors.
AID38222Inhibitory activity against aminopeptidase B1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis of sulfur-containing analogues of bestatin. Inhibition of aminopeptidases by alpha-thiolbestatin analogues.
AID1461818Inhibition of porcine kidney cortex aminopeptidase N using Leu-p-nitroanilide as substrate pretreated for 30 mins followed by substrate addition by fluorescence assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID1348417Antiproliferative activity against human U937 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID477788Inhibition of aminopeptidase N2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II.
AID38213Compound was evaluated for its inhibitory potency against purified membrane bound rat brain Aminopeptidase B using L-lysine-beta napthylamide as substrate1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID386437Antimalarial activity as inhibition of Plasmodium falciparum 3D7 replication in medium + isoleucine after 65 hrs2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID1626068Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 100 measured after 72 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID613980Inhibition of APN in human HL60 cells assessed as hydrolysis of L-Leu-p-nitroanilide by spectrophotometry2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.
AID712060Antiangiogenesis activity against HUVEC assessed as decrease in capillary tubular structure formation at 25 ug/ml after 8 hrs by microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1627505Inhibition of human ERAP1 expressed in African green monkey COS7 cells using aminoacyl-4-methylcoumaryl-7-amide as substrate after 15 mins by spectrofluorophotometric method2016ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7
Screening Identifies Thimerosal as a Selective Inhibitor of Endoplasmic Reticulum Aminopeptidase 1.
AID712062Inhibition of mouse B16-BL6 cell invasion at 100 mg/ml by Matrigel invasion assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID339515Inhibition of pig kidney microsomes aminopeptidase N2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Novel aminopeptidase N inhibitors derived from 1,3,4-thiadiazole scaffold.
AID408409Inhibition of aminopeptidase N2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors.
AID665652Inhibition of APN in human ES2 cell surface using L-Leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by UV/VIS spectrophotometry2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.
AID1497804Inhibition of APN in human PLC/PRF/5 cells using L-Leu-pnitroanilide as substrate pretreated for 5 mins followed by substrate addition measured after 1 hr2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1380364Solubility in PBS2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design of Aminopeptidase N Inhibitors as Anti-cancer Agents.
AID389011Antiproliferative activity against human HL-60 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN).
AID1572699Antiproliferative activity against human H7402 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID1348466AUC (0 to infinity) in Wistar rat at 80 mg/kg, iv after 0.05 to 24 hrs by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID681124TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID1713145Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1461822Inhibition of Plasmodium falciparum M1 aminopeptidase at 20 uM using Arg-AMC as substrate measured after 5 mins by fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID1572690Inhibition of porcine kidney microsomal APN using L-Leu-p-nitroanilide as substrate after 30 mins2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID397941Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11
Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors.
AID613978Inhibition of human MMP-2 after 30 mins by spectrophotometry2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.
AID415444Inhibition of MMP2 by spectrophotometry2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).
AID1500910Inhibition of recombinant human N-terminal His6-MBP-tagged PSA expressed in Escherichia coli BL21 STAR (DE3) using 4-Ala-MNA as substrate measured for 30 mins by thefluorescence assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
AID619825Inhibition of pig kidney microsome aminopeptidase N using L-Leu-p-nitroanilide substrate2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.
AID1500916Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
AID242403Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells; ND:Not determined2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID573047Inhibition of leucyl aminopeptidase activity in Plasmodium falciparum 3D7 at 10 uM using Leu-AMC as a substrate by spectrophotometer2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
AID1572725Synergistic antitumor activity against mouse H22 cells transplanted in Kunming mouse at 47 mg/kg, ip co-administered with 5-Fu at 20 mg/kg, ip for 14 consecutive days2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID587097Inhibition of Plasmodium falciparum recombinant M1-aminopeptidase expressed in Escherichia coli after 40 mins uisng fluorogenic substrate L-Leucyl-7-amido-40-methylcoumarin by fluorescence spectrophotometry2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Synthesis of new (-)-bestatin-based inhibitor libraries reveals a novel binding mode in the S1 pocket of the essential malaria M1 metalloaminopeptidase.
AID38364Inhibitory activity against aminopeptidase N (APN) in human acute lymphoblastic leukemia MOLT-4 cell line1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID437269Inhibition of aminopeptidase N in pig kidney microsome by spectrophotometry2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.
AID1348418Antiproliferative activity against human U266 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID38377Inhibitory activity against aminopeptidase N assayed by the L-Ala-MCA method.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton.
AID588971Substrates of transporters of clinical importance in the absorption and disposition of drugs, PEPT22010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1845873Inhibition of Plasmodium falciparum alanyl aminopeptidase assessed as inhibition constant using H-Leu-NHMec as substrate by spectrofluorimeter based analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Metalloaminopeptidases of the Protozoan Parasite
AID1348409Antiproliferative activity against human ES2 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID712065Inhibition of human ES2 cell migration at 150 uM by crystal violet staining based microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1348471Terminal Half life in Wistar rat at 80 mg/kg, iv after 0.05 to 24 hrs by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1774963Inhibition of APN in pig kidney microsomes assessed as reduction in p-nitroanilide release using L-leu-p-nitroanilide as substrate incubated for 30 mins by UV absorption based analysis2021ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID1461812Hemolytic activity against human erythrocytes at 25 uM measured after 48 hrs2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID1461808Inhibition of recombinant Plasmodium falciparum M1 aminopeptidase assessed as residual activity at 20 uM using Ala-AMC as substrate pretreated for 30 mins followed by substrate addition by fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID35664Compound was evaluated for its inhibitory potency against purified membrane bound rat brain APs1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID1461816Antimalarial activity against asynchronized chloroquine-resistant Plasmodium falciparum FcB1/Columbia assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 24 hrs followed by [3H]-hypoxanthine addition after 24 hrs by microbeta scintilla2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID1893373Inhibition of recombinant IRAP (unknown origin) expressed in HEK293S cells using L-AMC as substrate by flourescence assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin.
AID1630736Antiproliferative activity against HLMEC after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID752017Inhibition of APN in human ES-2 cells using L-Leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by UV-Vis spectrophotometry2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID278818Antimalarial activity against Plasmodium falciparum Dd22007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID1572717Antiangiogenic activity in Sprague-Dawley rat thoracic aorta assessed as decrease in micro-vessels growth at 100 uM after 9 days by inverted microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID1276239Inhibition of APN in porcine kidney microsomes preincubated for 5 mins before L-leu-p-nitroanilide substrate addition for 30 mins by plate reader analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID389010Inhibition of MMP22008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN).
AID1497803Inhibition of APN in human ES2 cells using L-Leu-pnitroanilide as substrate pretreated for 5 mins followed by substrate addition measured after 1 hr2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1845882Antimalarial activity against Plasmodium falciparum 3D7 incubated for 48 hrs by [3H]hypoxanthine incorporation assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Metalloaminopeptidases of the Protozoan Parasite
AID1572715Antiangiogenic activity against HUVEC assessed as inhibition of tube formation at 100 uM after 4 hrs by inverted microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID1497808Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID56226Inhibitory activity against Dipeptidylpeptidase IV (DPP IV) in human acute lymphoblastic leukemia MOLT-4 cell line1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID1774971Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID38237Compound was evaluated for its inhibitory potency against purified membrane bound rat brain Aminopeptidase M using [3H]Leu-enkephalin as substrate1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID1141243Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys (acetyl)-AMC as fluorogenic substrate after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
AID744377Cytotoxicity against human ES2 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN).
AID472434Inhibition of pig kidney aminopeptidase N using Leu-AMC as substrate2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13.
AID640442Antimetastatic activity against human H22 cells xenografted in mouse assessed as inhibition of metastasized nodes on lung surface dosed orally 6 days/week for 2 weeks2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID1713599Inhibition of CD13 in human PLC-PRF-5 cell surface using L-leucine-p-nitroanilide as substrate and measured after 1 hr by microplate reader analysis2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1348420Antiproliferative activity against human A549 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID588970Substrates of transporters of clinical importance in the absorption and disposition of drugs, PEPT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID701431Cytotoxicity against human ES2 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID779530Inhibition of Aeromonas proteolytica leucyl aminopeptidase using L-leucine para-notroanilide as substrate assessed as release of para-nitroaniline by Dixon plot analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis of amino-hydroxy-benzocycloheptenones as potent, selective, non-peptidic dinuclear zinc metalloaminopeptidase inhibitors.
AID752008Acute cytotoxicity against HUVEC at 100 ug/ml after 8 hrs by microscopic analysis2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID497183Inhibition of MMP2 after 30 mins2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.
AID307412Inhibition of MMP2 after 30 mins2007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.
AID110589Analgesic response measured as percentage change in reaction time (dose 100 ug given intracervically) after 30 min in mice1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID110590Analgesic response measured as percentage change in reaction time (dose 100 ug given intracervically) after 5 min in mice1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID1348456Drug level in Wistar rat plasma treated with (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin1(2H)-yl)methyl-2-((S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbut-anamido)-4-methylpentanamido)acetate hydrochloride assessed as peptidase-mediated compound formation at 802018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID278816Antimalarial activity against Plasmodium falciparum D102007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID753548Antiangiogenic activity in human MDA-MB-435 cells xenografted in chicken embryo chorioallantoic membrane assessed as inhibition of blood vessel formation at 20 mg/kg measured after 2 days2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor.
AID1348404Inhibition of CD13 on surface of human PLC/PRF/5 cells using L-leucine-p-nitroanilide as substrate after 1 hr2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1322073Binding affinity to human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H at 15 degC by ITC method2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1348411Antiproliferative activity against human U937 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID35689Inhibition of partially purified soluble aminopeptidase from rat brain1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Design of novel inhibitors of aminopeptidases. Synthesis of peptide-derived diamino thiols and sulfur replacement analogues of bestatin.
AID462891Inhibition of protein farnesyltransferase by continuous fluorescence assay2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
AID1590296Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 100 ug/ml incubated for 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Chemically synthesized LYRM03 could inhibit the metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
AID1713593Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1497805Antiproliferative activity against human U937 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID477791Antimetastatic activity against mouse H22 cells transplanted in mouse lung assessed as inhibition of tumor growth on the surface of lungs at 50 mg/kg/day, po for 6 days a week for 2 weeks2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II.
AID241143Inhibitory concentration against aminopeptidase N2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID1607843Inhibition of Plasmodium falciparum M1 aminopeptidase2019Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
AID1630761Antiproliferative activity against human LoVo/DX cells at 290 uM2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID1713147Antiproliferative activity against human HEL cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1441655Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in pathological changes at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs by hematoxylin and eosin staining based micro2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID307413Ratio of IC50 for microsomal aminopeptidase to IC50 for MMP22007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.
AID386434Inhibition of aminopeptidase N in Plasmodium falciparum food vacuole extract2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID1276243Antimetastasis activity against mouse H22 cells implanted in mouse assessed as inhibition of tumour growth at 80 mg/kg/day, po administered 6 days/week for 2 weeks2016European journal of medicinal chemistry, Jan-27, Volume: 108Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID242422Inhibition of human matrix metalloprotease-14 expressed in Escherichia coli; ND=Not determined2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID1612700Inhibition of recombinant Escherichia coli M1 aminopeptidase using Leu-pNA as substrate preincubated for 15 mins followed by substrate addition2019European journal of medicinal chemistry, Feb-01, Volume: 163Discovery of potent and selective inhibitors of the Escherichia coli M1-aminopeptidase via multicomponent solid-phase synthesis of tetrazole-peptidomimetics.
AID701236Cytotoxicity against human K562 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID38378Inhibitory activity against mammalian Aminopeptidase N (APN)2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors.
AID1322071Binding affinity to human C-terminal His6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H assessed as change in melting temperature at 500 uM by sypro orange dye based differential scanning fluorimetric analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID477793Antimetastatic activity against human ES2 cells xenografted in mouse lung assessed as inhibition of tumor growth at 50 mg/kg/day, po for 6 days a week for 2 weeks2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II.
AID453299Inhibition of MMP22009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.
AID1497812Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID744380Inhibition of pig kidney microsome aminopeptidase-N using L-leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN).
AID1713157Anti-angiogenesis activity in Wistar rat thoracic aortic rings assessed as decrease in number of microvessels sprouting at 20 ug/ml treated every other day for 9 days2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID551697Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors.
AID1630731Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID701220Antimetastatic activity in human MDA-MB-231 cells assessed as inhibition of cell invasion at 300 uM after 20 hrs by matrigel assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID590643Competitive inhibition of pig kidney LAP activity using l-Leucine-p-nitroanilide as substrate after 10 mins by Michaelis-Menten equation2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Small-molecule probe using dual signals to monitor leucine aminopeptidase activity.
AID440778Antimetastatic activity in mouse H22 cells xenografted in mouse assessed as reduction of metastasized nodes at 50 mg/kg, po administered 6 days per week for 2 weeks measured after 1 day last post dose2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID101207Binding affinity for cytosolic leucine aminopeptidase (LAP) from porcine kidney2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
AID1276240Inhibition of HDAC1/HDAC2 in human HeLa cells nuclear extract preincubated for 5 mins before Boc-Lys (acetyl)-AMC substrate addition for 30 mins by microplate reader analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID729520Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN).
AID752011Antiinvasive activity against human ES2 cells in matrigel-coated transwell chamber after 8 hrs by Crystal violet staining-based microscopy2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID1713598Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID701235Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID415652Inhibition of pig kidney microsomal aminopeptidase N after 30 mins by UV-VIS spectrophotometry2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).
AID101204Inhibitory activity against Leucine aminopeptidase1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis of sulfur-containing analogues of bestatin. Inhibition of aminopeptidases by alpha-thiolbestatin analogues.
AID110600Analgesic response measured as percentage change in reaction time (dose 25 ug given intracervically) after 60 min in mice1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID744379Inhibition of aminopeptidase-N in human ES2 cells using L-leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN).
AID1630742Antiproliferative activity against human MCF10 cells at 290 uM after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID415443Inhibition of pig kidney microsome aminopeptidase N by UV-visible spectrophotometer2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID38221Inhibition of aminopeptidase B or arginyl aminopeptidase purified from rat liver1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements.
AID573048Inhibition of leucyl aminopeptidase activity in Plasmodium falciparum 3D7 at 0.1 uM using Leu-AMC as a substrate by spectrophotometer2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
AID1572697Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID712064Inhibition of human ES2 cell invasion at 15 to 150 uM after 8 hrs by Matrigel invasion assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1774973Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID568369Inhibition of bovine lens cytosolic leucine aminopeptidase by Dixon plot analysis2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Amino-benzosuberone: a novel warhead for selective inhibition of human aminopeptidase-N/CD13.
AID1845884In vivo antiplasmodial activity against Plasmodium chabaudi chabaudi infected in C57/BL6J mouse assessed as reducing parasitaemia at 100 mg/kg, po administered for 4 days relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Metalloaminopeptidases of the Protozoan Parasite
AID1713141Inhibition of CD13 in human ES-2 cell surface using L-leucine-p-nitroanilide as substrate and measured after 1 hr by microplate reader analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1713600Inhibition of CD13 in human A549 cell surface using L-leucine-p-nitroanilide as substrate and measured after 1 hr by microplate reader analysis2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID619827Inhibition of aminopeptidase N in human ES2 cells assessed as L-Leu-p-nitroanilide hydrolysis2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.
AID1497801Inhibition of APN in porcine kidney microsomes using L-Leu-pnitroanilide as substrate pretreated for 5 mins followed by substrate addition measured after 30 mins2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1612712Growth inhibition of Escherichia coli BL21 up to 100 uM after 3 to 20 hrs by spectrophotometric analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Discovery of potent and selective inhibitors of the Escherichia coli M1-aminopeptidase via multicomponent solid-phase synthesis of tetrazole-peptidomimetics.
AID1461817Antimalarial activity against synchronized ring stage of chloroquine-resistant Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs by Giemsa staining based microscopic analysis2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID158851Inhibitory activity against Plasmodium falciparum FcB12003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors.
AID712067Cytotoxicity against human ES2 cells assessed as cell growth inhibition rate at 50 ug/ml after 24 hrs by MTT assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID711160Cytotoxicity against human MRC5 SV2 cells after 72 hrs by resazurin fluorimetric analysis2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors.
AID1572695Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID284233Inhibition of microsomal neural aminopeptidase in pig kidney2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening.
AID729522Inhibition of HDAC1/HDAC3/HDAC5/HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate measured after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN).
AID1572700Antiproliferative activity against HUVEC after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID456586Inhibition of APN from pig kidney microsomes by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors.
AID701434Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID665655Antimetastatic activity against human ES2 cells assessed as inhibition of migration through transwell chamber without matrigel coating at 100 ug/mL after 3 hrs by crystal voilet staining2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.
AID1658567Inhibition of recombinant human full length C-terminal His6-tagged LTA4H expressed in Escherichia coli BL21 DE3 cells assessed as reduction in amino-4-methylcoumarin formation using L-arginine-7-amino-4-methylcoumarin as substrate incubated for 30 mins fo2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.
AID665651Inhibition of pig kidney APN using L-Leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by UV/VIS spectrophotometry2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.
AID701233Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID1133939Inhibition of leucine aminopeptidase B (unknown origin) using 0.2 mM L-leucine-beta-naphthylamide1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B.
AID587099Antimalarial activity against Plasmodium falciparum 3D7 infected-erythrocytes after 72 hrs by SYBR green fluorescence method2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Synthesis of new (-)-bestatin-based inhibitor libraries reveals a novel binding mode in the S1 pocket of the essential malaria M1 metalloaminopeptidase.
AID1337014Cytotoxicity against human HF19 cells assessed as reduction in cell viability after 48 hrs by WST1 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis, docking, cytotoxicity, and LTA
AID1713150Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1248349Inhibition of human full length MMP2 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID752013Antimigratory activity against human ES2 cells in transwell chamber at 100 ug/ml after 3 hrs by Crystal violet staining-based microscopy2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID681125TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID1630741Antiproliferative activity against human MCF7 cells at 290 uM after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID456587Inhibition of MMP2 by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors.
AID729519Antiproliferative activity against human U937 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN).
AID38354Inhibition of aminopeptidase M or membrane leucine aminopeptidase1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements.
AID1441660Inhibition of LTB4 biosynthesis in LPS-induced C57BL/6 mouse model of acute lung injury BLAF at 25 mg/kg, ip by ELISA2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1348416Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1348468VRT (0 to infinity) in Wistar rat at 80 mg/kg, iv after 0.05 to 24 hrs by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID613979Selectivity ratio of IC50 for MMP-2 to IC50 for pig kidney microsomal APN2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.
AID701435Inhibition of aminopeptidase in human HL60 cells2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID712058Antiangiogenic activity against mouse B16-BL6 cells xenografted in C57BL/6 mouse assessed as decrease in number of vessels oriented towards the tumor mass at 100 mg/kg/day, ip administered for 4 days measured on day 5 by dissecting microscopic analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1133938Inhibition of rat liver aminopeptidase B using 0.2 mM L-leucine-beta-naphthylamide by colorimetry1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1348431Induction of apoptosis in human PLC/PRF/5 cells assessed as late apoptotic cells at 20 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 0.341%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1630733Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID1497816Antiangiogenic activity in Sprague-Dawley rat thoracic aorta ring assessed as reduction in micro-vessel growth at 100 uM supplemented with fresh medium containing compound every 3 for 9 days measured on day 9 by matrigel-based inverted microscopic analysi2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID764647Inhibition of HDAC1/HDAC3/HDAC5/HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate measured after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN).
AID779531Inhibition of porcine kidney APN using L-leucine para-notroanilide as substrate assessed as release of para-nitroaniline by Dixon plot analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis of amino-hydroxy-benzocycloheptenones as potent, selective, non-peptidic dinuclear zinc metalloaminopeptidase inhibitors.
AID1626063Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 100 measured after 48 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID613982Antiproliferative activity against human MDA-MB-231 cells expressing low levels of APN after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.
AID339516Inhibition of MMP22008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Novel aminopeptidase N inhibitors derived from 1,3,4-thiadiazole scaffold.
AID1845881Inhibition of recombinant Plasmodium falciparum A-M1 assessed as inhibition constant using H-Leu-NHMec as substrate2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Metalloaminopeptidases of the Protozoan Parasite
AID1630760Antiproliferative activity against human LoVo cells at 290 uM2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID729523Inhibition of pig microsomal aminopeptidase N using L-leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN).
AID701438Inhibition of porcine kidney microsome aminopeptidase using L-Leu-p-nitroanilide as substrate after 30 mins2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID38226Inhibitory activity against Aminopeptidase M1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis of sulfur-containing analogues of bestatin. Inhibition of aminopeptidases by alpha-thiolbestatin analogues.
AID701432Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID386438Antimalarial activity as inhibition of Plasmodium falciparum 3D7 replication in medium with all amino acids after 65 hrs2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID1348437Induction of apoptosis in human PLC/PRF/5 cells assessed as viable cells at 20 uM in presence of 5-FU after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 93.7%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1617648Inhibition of LTB4 production in A23187-stimulated human neutrophils at 0.001 to 1000 microM incubated for 30 mins by ELISA2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Effect of Modifier Structure on the Activation of Leukotriene A
AID1713594Antiproliferative activity against human 3AO cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID362195Inhibition of human recombinant leukotriene A4 hydrolase2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and biological evaluation of N-mercaptoacylproline and N-mercaptoacylthiazolidine-4-carboxylic acid derivatives as leukotriene A4 hydrolase inhibitors.
AID1348470Volume of distribution during elimination phase in Wistar rat at 80 mg/kg, iv after 0.05 to 24 hrs by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID679327TP_TRANSPORTER: uptake in PEPT1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
AID701237Cytotoxicity against human NB4 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID701222Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 300 uM after 24 hrs using annexin-V-FITC staining by flow cytometry (Rvb = 1.69%)2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1500911Inhibition of recombinant human C-terminal His10-tagged APN (Lys69 to Lys967 residues) at 10 uM using Ala-AMC as substrate measured for 20 mins by fluorescence assay relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
AID1133940Retardation factor, Rf value of the compound using BuOH-AcOH-H20 at 4:1:1 ratio by ninhydrin1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B.
AID1276242Antiinvasive activity against human ES2 cells assessed as reduction in cell invasion at 150 uM after 8 hrs by crystal violet staining based Matrigel assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID613981Antiproliferative activity against human HL60 cells expressing high levels of APN after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1348432Induction of apoptosis in human PLC/PRF/5 cells assessed as necrotic cells at 20 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 0.106%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID712070Inhibition of APN in human ES2 cell surface assessed as inhibition of L-Leu-p-nitroanilide substrate hydrolysis incubated for 5 mins before substrate addition by UV-Vis spectrophotometric analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1348447Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 30 uM after 6 hrs by phase-contrast microscopic method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID415653Inhibition of MMP22009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).
AID678849TP_TRANSPORTER: uptake in Xenopus laevis oocytes1996Biochimica et biophysica acta, Apr-26, Volume: 1280, Issue:2
Molecular cloning and tissue distribution of rat peptide transporter PEPT2.
AID573054Inhibition of leucyl aminopeptidase activity in Plasmodium falciparum 3D7 harboring tPfAP-M17 gene at 0.1 uM using Leu-AMC as a substrate by spectrophotometer in presence of 1 nM CoCl22008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
AID1626059Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 100 measured after 24 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1713589Antiproliferative activity against human U937 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID573052Inhibition of leucyl aminopeptidase activity in Plasmodium falciparum 3D7 at 0.1 uM using Leu-AMC as a substrate by spectrophotometer in presence of 1 nM CoCl22008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
AID1348472Cmax in Wistar rat at 80 mg/kg, iv after 0.05 to 24 hrs by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID568371Inhibition of Aeromonas proteolytica aminopeptidase by Dixon plot analysis2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Amino-benzosuberone: a novel warhead for selective inhibition of human aminopeptidase-N/CD13.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1713152Antiproliferative activity against human H7402 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1630762Antiproliferative activity against human A549 cells at 290 uM2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID1713597Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID704974Competitive inhibition of pig APN using L-leucine-p-nitroanilide as substrate by Dixon-plot analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
Rapid and efficient synthesis of a novel series of substituted aminobenzosuberone derivatives as potent, selective, non-peptidic neutral aminopeptidase inhibitors.
AID386436Inhibition of DPAP1 assessed as blocking of release of beta-naphthylamine from Ala-Pro-Ala-betaNA substrate at 1 uM in presence of recombinant Plasmodium falciparum aminopeptidase P2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID1713148Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1497811Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID712059Inhibition of APN in mouse B16-BL6 cell surface assessed as inhibition of L-Leu-p-nitroanilide substrate hydrolysis incubated for 5 mins before substrate addition by UV-Vis spectrophotometric analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1348412Antiproliferative activity against human U266 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID389009Inhibition of pig kidney microsome aminopeptidase N by UV-visible spectrophotometer2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN).
AID590644Competitive inhibition of pig kidney LAP activity using DCDHF-Leu as substrate after 10 mins by Michaelis-Menten equation2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Small-molecule probe using dual signals to monitor leucine aminopeptidase activity.
AID1337012Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by WST1 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis, docking, cytotoxicity, and LTA
AID1713590Antiproliferative activity against human U266 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID724223Inhibition of human LTA4H epoxide hydrolase activity using LTA4 as substrate incubated for 15 mins prior to substrate addition measured after 10 mins by ELISA2013European journal of medicinal chemistry, Jan, Volume: 59Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.
AID1893372Inhibition of recombinant ERAP2 (unknown origin) expressed in baculovirus infected Hi-5 insect cells using R-AMC as substrate by flourescence assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin.
AID590642Competitive inhibition of pig kidney LAP activity using N-(6-Methoxypyridine-3-yl), (S)-2-amino-4-methylpentanamide as substrate after 10 mins by Michaelis-Menten equation2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Small-molecule probe using dual signals to monitor leucine aminopeptidase activity.
AID1497814Antiangiogenic activity in HUVEC assessed as inhibition of capillary-like tube formation at 100 uM after 4 hrs by matrigel-based assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1572692Inhibition of APN on human ES-2 cell surface using L-Leu-p-nitroanilide as substrate after 1 hr2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1276241Inhibition of APN in human ES2 cells preincubated for 5 mins before L-leu-p-nitroanilide substrate addition for 1 hr by photometry2016European journal of medicinal chemistry, Jan-27, Volume: 108Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID704972Competitive inhibition of bovine LAPc using L-leucine-p-nitroanilide as substrate by Dixon-plot analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
Rapid and efficient synthesis of a novel series of substituted aminobenzosuberone derivatives as potent, selective, non-peptidic neutral aminopeptidase inhibitors.
AID472435Cytotoxicity against human PANC1 cells assessed as cell growth inhibition after 72 hrs by XTT assay2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13.
AID437270Inhibition of MMP22009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.
AID1713601Inhibition of porcine kidney microsomal CD13 using L-leucine-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by microplate reader analysis2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1626057Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1348414Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1572719Anti-invasive activity against human ES2 cells at 100 uM after 8 hrs by crystal violet staining-based inverted microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID1348443Downregulation of CD13 expression in human PLC/PRF/5 cells at 10 uM after 48 hrs by flow cytometric method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID573051Inhibition of leucyl aminopeptidase activity in Plasmodium falciparum 3D7 at 10 uM using Leu-AMC as a substrate by spectrophotometer in presence of 1 nM CoCl22008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
AID440777Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.
AID1774974Anti-angiogenic activity against HUVEC cells assessed as inhibition of tubular structure formation at 10 uM incubated for 6 days by Matrigel based phase contrast microscopic analysis2021ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID568368Inhibition of human aminopeptidase N by Dixon plot analysis2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Amino-benzosuberone: a novel warhead for selective inhibition of human aminopeptidase-N/CD13.
AID1348422Antiproliferative activity against human HepG2 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1713596Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1774972Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID1348467MRT (0 to infinity) in Wistar rat at 80 mg/kg, iv after 0.05 to 24 hrs by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID752010Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 100 ug/ml after 8 hrs by microscopic analysis2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID1380365Inhibition of APN in porcine kidney microsomes using L-leucine-p-nitroanilide as substrate preincubated for 30 mins followed by substrate addition by UV-visible spectrophotometric method2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design of Aminopeptidase N Inhibitors as Anti-cancer Agents.
AID440776Inhibition of pig kidney microsomes aminopeptidase N preincubated for 30 mins2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.
AID386435Inhibition of DPAP1 assessed as blocking of release of beta-naphthylamine from Ala-Pro-Ala-betaNA substrate at 1 uM2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID712068Inhibition of recombinant MMP-2 using succinylated gelatin as substrate incubated for 10 mins before addition of substrate measured after 60 mins by UV-Vis spectrophotometric analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1574643Reversible inhibition of Plasmodium falciparum C-terminal His6-tagged M17 aminopeptidase (85 to 605 residues) expressed in Escherichia coli BL21(DE3) assessed as enzyme activity recovery at 150 uM preincubated followed by compound washout for 5 hrs and su2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1141241Inhibition of MMP2 (unknown origin) using succinylated gelatin as substrate preincubated for 10 mins before substrate addition measured after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
AID408408Inhibition of MMP22008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors.
AID497184Cytotoxicity against human HL60 cells expressing aminopeptidase N after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.
AID1713146Antiproliferative activity against human 3AO cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID414665Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Design, synthesis and SAR studies of tripeptide analogs with the scaffold 3-phenylpropane-1,2-diamine as aminopeptidase N/CD13 inhibitors.
AID1461809Antimalarial activity against synchronized ring stage of chloroquine-resistant Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth at 25 uM after 72 hrs by YOYO-1 staining based flow cytometric analysis relative to control2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID242402Inhibition of human matrix metalloprotease-2 expressed in Sf9 insect cells; ND:Not determined2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID110599Analgesic response measured as percentage change in reaction time (dose 25 ug given intracervically) after 5 min in mice1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID619829Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.
AID1572698Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID679882TP_TRANSPORTER: inhibition of Ceftibuten uptake (Ceftibuten: 1000 uM, Bestatin: 10000 uM) in PEPT1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
AID1713154Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID551696Inhibition of porcine kidney microsomal APN after 10 mins at room temperature by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors.
AID679868TP_TRANSPORTER: inhibition of Cephradine uptake (Cephradine: 3000 uM, Bestatin: 10000 uM) in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID701429Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID1713142Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1348413Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID386440Antimalarial activity as DNA content of ring stage Plasmodium falciparum 3D7 in medium with all amino acids by flow cytometry2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID1348434Induction of apoptosis in human PLC/PRF/5 cells assessed as early apoptotic cells at 20 uM in presence of 5-FU after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 5.82%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID110598Analgesic response measured as percentage change in reaction time (dose 25 ug given intracervically) after 30 min in mice1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID56211Inhibitory activity against dipeptidyl peptidase IV (DPP- IV)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton.
AID219416Cytotoxicity in human embryonic lung flbroblast Wl-38 cells using WST-1 viability assay1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID1607842Inhibition of soluble human APN ectodomain stably expressed in HEK293 GnTI(-) cells using H-Leu-NHMec as substrate preincubated for 10 mins followed by substrate addition and measured for 1 hr by spectrofluorimetric method2019Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
AID1713602Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID712069Cytotoxicity against human ES2 cells assessed as cell growth inhibition rate at 5 ug/ml after 24 hrs by MTT assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1713588Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1461820Selectivity index, ratio of Ki for recombinant Plasmodium falciparum M1 aminopeptidase to Ki for porcine kidney cortex aminopeptidase N2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID406526Inhibition of pig kidney aminopeptidase N2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
First synthesis of alpha-aminoalkyl-(N-substituted)thiocarbamoyl-phosphinates: inhibitors of aminopeptidase N (APN/CD13) with the new zinc-binding group.
AID1497817Anti-metastatic activity against mouse H22 cells implanted in Kunming mouse assessed as reduction in number of metastatic nodes at 60 mg/kg, ip administered once daily for 12 days measured on day 13 by bouin's staining based assay relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID711021Inhibition of Plasmodium falciparum recombinant AM1 using Leu-pNA as substrate2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors.
AID1337015Selectivity index, ratio of IC50 for human TIG1 cells to IC50 for human HCT116 cells2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis, docking, cytotoxicity, and LTA
AID1497807Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1348406Antiproliferative activity against human PLC/PRF/5 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1337013Cytotoxicity against human TIG1 cells assessed as reduction in cell viability after 48 hrs by WST1 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis, docking, cytotoxicity, and LTA
AID1322075Binding affinity to human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H at 35 degC by ITC method2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1713605Induction of apoptosis in human PLC-PRF-5 cells assessed as late apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 8.7 %)2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1590314Inhibition of human APN in MDA-MB-231 cells at 50 ug/ml using L-leucine-p-nitroanilide as a substrate incubated for 1 hr by spectrophotometric method relative to control2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Chemically synthesized LYRM03 could inhibit the metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
AID701234Cytotoxicity against human PC3 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID1572693Inhibition of APN on human PLC/PRF/5 cell surface using L-Leu-p-nitroanilide as substrate after 1 hr2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID679881TP_TRANSPORTER: inhibition of Ceftibuten uptake (Ceftibuten: 1000 uM, Bestatin: 10000 uM) in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID701430Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID665653Inhibition of recombinant MMP2 using succinylated gelatin as substrate incubated for 10 mins prior to substrate addition measured after 1 hr by UV/VIS spectrophotometry2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.
AID497182Inhibition of pig kidney microsome aminopeptidase N after 30 mins by UV-vis spectrophotometric analysis2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.
AID1572696Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID1893371Inhibition of recombinant ERAP1 (unknown origin) expressed in baculovirus infected Hi-5 insect cells using L-AMC as substrate by flourescence assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin.
AID1348402Inhibition of porcine kidney CD13 using L-leucine-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID453298Inhibition of porcine kidney microsome APN assessed as L-Leu-p-nitroanilide hydrolysis2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.
AID1713151Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1248351Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1248352Inhibition of human full length MMP2 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1348415Antiproliferative activity against human H7402 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1630732Antiproliferative activity against human HL60/MX2 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID1337016Inhibition of recombinant C-terminal His-tagged human LTA4H aminopeptidase activity expressed in Escherichia coli using L-alanine-4-nitro-anilide hydrochloride as substrate preincubated for 20 mins followed by substrate addition2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis, docking, cytotoxicity, and LTA
AID1461823Inhibition of Plasmodium falciparum M1 aminopeptidase using Ala-AMC as substrate by spectrofluorimetric assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
AID1500917Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
AID679873TP_TRANSPORTER: inhibition of Cephradine uptake (Cephradine: 1000 uM, Bestatin: 10000 uM) in PEPT1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
AID613977Inhibition of pig kidney microsomal APN assessed as hydrolysis of L-Leu-p-nitroanilide after 1 hr by spectrophotometry2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.
AID1497806Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1441705Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in pathological changes at 25 mg/kg, ip and co-treated with ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid pretreated for 1 hr 2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1348405Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID640441Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID1348403Inhibition of CD13 on surface of human ES2 cells using L-leucine-p-nitroanilide as substrate after 1 hr2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID752015Cytotoxicity against human ES2 cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID1630730Inhibition of porcine kidney microsomal LAP using l-leucine-7-amido-4-methylcoumarin as substrate incubated for 60 mins measured every 3 mins by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID1348430Induction of apoptosis in human PLC/PRF/5 cells assessed as early apoptotic cells at 20 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 5.82%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID712066Selectivity ratio of IC50 for porcine kidney APN to IC50 for recombinant MMP-22012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID1761034Inhibition of recombinant ERAP2 (unknown origin) expressed in baculovirus infected insect cells at 2 mM using R-AMC as substrate preincubated for 30 mins followed by substrate addition and measured every 3 mins for 1 hr by flourescence assay relative to c2021European journal of medicinal chemistry, Feb-05, Volume: 211Modulators of hERAP2 discovered by high-throughput screening.
AID701223Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 300 uM after 24 hrs using annexin-V-FITC staining by flow cytometry (Rvb = 1.69%)2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID278817Antimalarial activity against Plasmodium falciparum FAC82007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID701232Cytotoxicity against human A549 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID1497810Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1713592Antiproliferative activity against human HEL cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID1348435Induction of apoptosis in human PLC/PRF/5 cells assessed as late apoptotic cells at 20 uM in presence of 5-FU after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 0.341%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID110591Analgesic response measured as percentage change in reaction time (dose 100 ug given intracervically) after 60 min in mice1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.
AID764648Inhibition of pig microsomal aminopeptidase N using L-leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN).
AID1348433Induction of apoptosis in human PLC/PRF/5 cells assessed as viable cells at 20 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 93.7%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1845880Antimalarial activity against Plasmodium falciparum D10 incubated for 48 hrs by [3H]hypoxanthine incorporation assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Metalloaminopeptidases of the Protozoan Parasite
AID1348469Apparent clearance in Wistar rat at 80 mg/kg, iv after 0.05 to 24 hrs by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1590310Antimetastatic activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as reduction in metastasis foci formation in lungs at 100 mg/kg, ip administered 3 times per week by hematoxylin-eosin staining based assay2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Chemically synthesized LYRM03 could inhibit the metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
AID753547Antitumor activity against human MDA-MB-435 cells xenografted in chicken embryo chorioallantoic membrane assessed as inhibition of tumor volume at 20 mg/kg measured after 2 days2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor.
AID1713591Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID619826Inhibition of MMP2 after 30 mins2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1572694Antiproliferative activity against human PLC cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID1713606Induction of apoptosis in human PLC-PRF-5 cells assessed as necrotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 6.1 %)2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
AID414664Inhibition of pig kidney microsomal APN2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Design, synthesis and SAR studies of tripeptide analogs with the scaffold 3-phenylpropane-1,2-diamine as aminopeptidase N/CD13 inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID101332Inhibition of leucine aminopeptidase1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements.
AID1845859Inhibition of recombinant Plasmodium falciparum A-M1 assessed as inhibition constant2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Metalloaminopeptidases of the Protozoan Parasite
AID1630729Inhibition of porcine kidney microsomal LAP using l-leucine-7-amido-4-methylcoumarin as substrate incubated for 10 hrs measured every 6 mins by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID1348407Antiproliferative activity against human PLC/PRF/5 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1337017Inhibition of recombinant C-terminal His-tagged human LTA4H epoxide hydrolase activity expressed in Escherichia coli assessed as reduction in LTB4 production using LTA4 as substrate preincubated for 20 mins followed by substrate addition measured after 302017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis, docking, cytotoxicity, and LTA
AID1348436Induction of apoptosis in human PLC/PRF/5 cells assessed as necrotic cells at 20 uM in presence of 5-FU after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 0.106%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID307411Inhibition of pig kidney microsomal aminopeptidase assessed as liberation of p-nitroanilide2007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.
AID38365In vitro inhibition of aminopeptidase N (APN) activity in intact U937 cells in presence of Ala-pNA and 10e-3 M concentration of compound2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13.
AID701433Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID701226Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2 phase at 300 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 18.35%)2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID712132Inhibition of mouse APN2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.
AID573050Inhibition of alanyl aminopeptidase activity in Plasmodium falciparum 3D7 at 0.1 uM using Ala-AMC as a substrate by spectrophotometer2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
AID497185Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.
AID568370Inhibition of aminopeptidase activity of human leukotriene A4 hydrolase by Dixon plot analysis2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Amino-benzosuberone: a novel warhead for selective inhibition of human aminopeptidase-N/CD13.
AID1348419Antiproliferative activity against human HCT116 cells in presence of 5-FU after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
AID1572721Anti-invasive activity against human ES2 cells at antiproliferative IC50 after 8 hrs by crystal violet staining-based inverted microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
AID665654Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.
AID1500913Toxicity in human HeLa cells expressing pCFE-GFP assessed as inhibition of GFP proetin synthesis at 25 uM incubated for 30 mins measured for 2 hrs by spectrophotometric method relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
AID752016Inhibition of pig kidney APN using L-Leu-p-nitroanilide as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by UV-Vis spectrophotometry2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
AID701436Inhibition of aminopeptidase in human ES-2 cells2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID1713143Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1713140Inhibition of porcine kidney microsomal CD13 using L-leucine-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by microplate reader analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID437271Selectivity ratio of IC50 for MMP2 to IC50 for aminopeptidase N in pig kidney microsome2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.
AID1713144Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
AID764645Inhibition of aminopeptidase N (unknown origin)2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN).
AID1500914Cytotoxicity against African green monkey Vero cells assessed as reduction in cell proliferation after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
AID1500912Inhibition of recombinant human C-terminal His10-tagged APN (Lys69 to Lys967 residues) using Ala-AMC as substrate measured for 30 mins by fluorescence assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
AID1630743Antiproliferative activity against mouse BALB/3T3 cells at 290 uM after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
AID35686Inhibitory activity against rabbit kidney aminopeptidase using 10 nM of [3H]Leu-enkephalin as substrate1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.
AID1322070Competitive inhibition of human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H using varying levels of L-arginine-7-amino-4-Methylcoumarine as substrate preincubated for 30 mins followed by substrate addition measured for 30 mins b2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1322076Binding affinity to human C-terminal His6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H assessed as change in melting temperature at 1 mM by circular dichroism spectroscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID724222Inhibition of human nonpancreatic secretory phospholipase A2 using 1,2-dimyristoyl-sn-glycero-3-phosphocholine as substrate after 10 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Jan, Volume: 59Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.
AID1248350Inhibition of porcine kidney microsomal APN using L-Leu-para-nitroanilide as substrate incubated for 2 hrs prior to substrate addition measured after 30 mins by plate reader analysis2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID701437Inhibition of porcine kidney microsome aminopeptidase using L-Leu-p-nitroanilide as substrate by Dixon method2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
A novel aminopeptidase N inhibitor developed by virtual screening approach.
AID420373Solubility in methanol2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
AID1497809Antiproliferative activity against human PLC cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1798383Enzyme Inhibition Assay from Article 10.1016/j.bmc.2006.06.050: \\Synthesis and structure activity relationships of novel non-peptidic metallo-aminopeptidase inhibitors.\\2006Bioorganic & medicinal chemistry, Nov-01, Volume: 14, Issue:21
Synthesis and structure activity relationships of novel non-peptidic metallo-aminopeptidase inhibitors.
AID1802060APN Inhibition Assay from Article 10.1111/cbdd.12778: \\Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.\\2016Chemical biology & drug design, 10, Volume: 88, Issue:4
Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.
AID1803042In Vitro APN Inhibition Assay from Article 10.3109/14756361003698147: \\Synthesis of a novel series of L-isoserine derivatives as aminopeptidase N inhibitors.\\2012Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 27, Issue:2
Synthesis of a novel series of L-isoserine derivatives as aminopeptidase N inhibitors.
AID1803263MMP-2 Inhibition Assay from Article 10.3109/14756366.2012.656622: \\Design, synthesis and preliminary activity evaluation of novel 3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as aminopeptidase N/CD13 inhibitors.\\2013Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 28, Issue:3
Design, synthesis and preliminary activity evaluation of novel 3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as aminopeptidase N/CD13 inhibitors.
AID1803290In Vitro APN Inhibition Assay from Article 10.3109/14756366.2012.680062: \\Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.
AID1803043In Vitro MMP-2 Inhibition Assay from Article 10.3109/14756361003698147: \\Synthesis of a novel series of L-isoserine derivatives as aminopeptidase N inhibitors.\\2012Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 27, Issue:2
Synthesis of a novel series of L-isoserine derivatives as aminopeptidase N inhibitors.
AID1803262APN Inhibition Assay from Article 10.3109/14756366.2012.656622: \\Design, synthesis and preliminary activity evaluation of novel 3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as aminopeptidase N/CD13 inhibitors.\\2013Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 28, Issue:3
Design, synthesis and preliminary activity evaluation of novel 3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as aminopeptidase N/CD13 inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811Experimentally measured binding affinity data derived from PDB2004Biochemistry, Aug-03, Volume: 43, Issue:30
Spectroscopic and X-ray crystallographic characterization of bestatin bound to the aminopeptidase from Aeromonas (Vibrio) proteolytica.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2004Biochemistry, Aug-03, Volume: 43, Issue:30
Spectroscopic and X-ray crystallographic characterization of bestatin bound to the aminopeptidase from Aeromonas (Vibrio) proteolytica.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (909)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990300 (33.00)18.7374
1990's254 (27.94)18.2507
2000's154 (16.94)29.6817
2010's167 (18.37)24.3611
2020's34 (3.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.30 (24.57)
Research Supply Index6.88 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index45.55 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (31.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials43 (4.62%)5.53%
Reviews0 (0.00%)6.00%
Reviews33 (3.55%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies13 (1.40%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
Other841 (90.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY) [NCT02664558]Phase 261 participants (Actual)Interventional2016-04-30Completed
Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patients With Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial [NCT03402204]Phase 364 participants (Actual)Interventional2014-04-01Completed
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) [NCT02736149]Phase 251 participants (Actual)Interventional2016-12-31Terminated(stopped due to Following the failure to demonstrate efficacy in EIG-UBX-001, the sponsor decided to terminate Study EIG-UBX-002.)
Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA) [NCT02700529]Phase 254 participants (Actual)Interventional2016-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02664558 (2) [back to overview]Change in 6-minute Walk Distance (6MWD)
NCT02664558 (2) [back to overview]Change in Pulmonary Vascular Resistance (PVR)
NCT02700529 (1) [back to overview]Change in Skin Thickness of the Calf of the Most Affected Leg, Measured by Skinfold Calipers
NCT02736149 (1) [back to overview]Treatment-emergent Adverse Events (TEAEs)

Change in 6-minute Walk Distance (6MWD)

Change in exercise capacity from baseline to Week 24 as determined by the 6MWD (NCT02664558)
Timeframe: Baseline to Week 24

Interventionmeters (Least Squares Mean)
Ubenimex-20.0
Placebo4.2

[back to top]

Change in Pulmonary Vascular Resistance (PVR)

Change from Baseline at End of Treatment in PVR Using Worst Case Imputation in the Modified Intent to Treat Population. PVR was assessed by hemodynamic measurements obtained via right heart catheterization. (NCT02664558)
Timeframe: Baseline to Week 24

Interventiondyn.sec/cm5 (Mean)
Ubenimex73.1
Placebo46.6

[back to top]

Change in Skin Thickness of the Calf of the Most Affected Leg, Measured by Skinfold Calipers

Change from baseline to Week 24 in skin thickness of the calf of the most affected leg, measured by skinfold calipers in the Skin-Thickness Intent-to-Treat (ST-ITT) population (patients with skin thickness >/= 10 mm at baseline) which comprised of 36 patients (16 ubenimex, 20 placebo). (NCT02700529)
Timeframe: Baseline through Week 24

Interventionmm (Mean)
Ubenimex-6.83
Placebo-7.75

[back to top]

Treatment-emergent Adverse Events (TEAEs)

Number of Patients with TEAEs collected for all patients and recorded on the Adverse Event Case Report Form (NCT02736149)
Timeframe: At least 24 weeks of open-label treatment with ubenimex followed by 4 weeks follow-up

InterventionParticipants (Count of Participants)
Ubenimex44

[back to top]